- 专利标题: MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT
-
申请号: US17937256申请日: 2022-09-30
-
公开(公告)号: US20230256001A1公开(公告)日: 2023-08-17
- 发明人: Mark K. SCHLEGEL , Maja JANAS , Vasant R. JADHAV , Muthiah MANOHARAN , Kallanthottathil G. RAJEEV , Muthusamy JAYARAMAN , Alexander V. KEL'IN , Shigeo MATSUDA , Klaus CHARISSE , Jayaprakash K. NAIR , Martin A. MAIER , Alfica SEHGAL , Christopher BROWN , Christopher THEILE , Stuart MILSTEIN
- 申请人: ALNYLAM PHARMACEUTICALS, INC.
- 申请人地址: US MA Cambridge
- 专利权人: ALNYLAM PHARMACEUTICALS, INC.
- 当前专利权人: ALNYLAM PHARMACEUTICALS, INC.
- 当前专利权人地址: US MA Cambridge
- 主分类号: A61K31/713
- IPC分类号: A61K31/713 ; C12N15/113
摘要:
One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The antisense strand of the dsRNA molecule comprises at least one thermally destabilizing nucleotide occurring at a seed region; the dsRNA comprises at least four 2′-fluoro modifications, and the sense strand of the dsRNA molecule comprises ligand, wherein the ligand is an ASGPR ligand. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.
信息查询